Skip to the main content.
Other Therapy Areas

Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.

Learn More →

1 min read

Talk with Veristat's Experts at the CDISC Interchange

Talk with Veristat's Experts at the CDISC Interchange

CDISC INterchange 2015

Visit Veristat at Booth #30

Join Veristat at the 2015 CDISC International Interchange conference which carries this year’s theme:

 "Smarter Research to Unlock Cures"  

The conference will cover many topics that Veristat is well-versed in, including:

  • The Work We Do Saves Lives, But We Must Do More
  • The Analysis Data Model (ADaM) and Study Data Tabulation Model (SDTM)
  • A CRO's Journey to Innovation through CDISC Standards
  • CRF to SDTM: A Practical CDISC Implementation

Stop by our booth #30 to speak with our data managers, data standards programmers, biostatisticians and statistical programmers about your CDISC needs.

Schedule a Meeting

Meet with Veristat at CDISC. Even if you are not attending, reach out today to schedule a meeting.

SCHEDULE MEETING

Why Choose Veristat for your CDISC Standardization Needs?

Veristat can help you:

  • Covert raw data from clinical trials to CDISC compliant SDTM datasets
  • Develop ADaM datasets in addition to integrated analyses of safety and efficacy
  • Design CDASH compliant forms & databases for streamlined data management and reporting

Veristat has never had a submission rejected by the FDA for lack of standardized structure compliance.

Veristat's Vision of the Future

Veristat's Vision of the Future

Veristat's Vision of the Future

Read More
Veristat is Growing! Veristat is Moving!

Veristat is Growing! Veristat is Moving!

Veristat is Growing! Veristat is Moving!

Read More
Pursuing Breakthrough Therapies for Rare Metabolic Diseases: Veristat's Role in a Landmark Clinical Study

Pursuing Breakthrough Therapies for Rare Metabolic Diseases: Veristat's Role in a Landmark Clinical Study

Discover how Veristat's innovative approach in a challenging Phase I/II clinical study for a rare metabolic disease resulted in high sponsor...

Read More